Due to rising health care costs, more Americans are researching their own health conditions — gastrointestinal being among the most prominent — and are likely to shop retailers that are willing to help them along the way.

While sales are up for the stomach remedies category, retailers that aid consumers in the health care decision-making process are at an advantage, retailers and industry experts said.

Overall, sales for the gastrointestinal tablets category for the 52 weeks ending March 25, 2007, were up 7.9% from a year ago to $1.7 million, according to Information Resources Inc., Chicago. Gastrointestinal liquid remedy sales were up 5.18% to $482.6 million.

“The general public is becoming more educated on topics like colon cancer, increasing incidences of acid reflux and the availability of probiotics, which stabilize intestinal digestion,” said Alan Smith, pharmacy category manager for Bi-Lo, Greenville, S.C. “This awareness is causing increased visits to the [stomach remedies] category.”

In addition, the change of products such as Prilosec OTC, from Procter & Gamble, Cincinnati, to over-the-counter from prescription-only medication, “has definitely opened the category to wider use,” said Jim Linden, director of pharmacy, Nash Finch Co., Edina, Minn.

Prilosec OTC was introduced in 2003. According to IRI, it is the top-selling antacid tablet, up 9.48% from last year to $1.05 billion. It is also the highest-earning single product being tracked by IRI in the category.

Laxative MiraLAX, from Schering-Plough HealthCare Products, Kenilworth, N.J., went over-the-counter in late March and may provide a sales boost to complementary items like multivitamins and calcium and fiber mixes, Smith said.

“MiraLAX is a long-prescribed formula that chronic users are very familiar with, and will help folks that have tried gritty mixes or can't swallow pills,” Smith said. “The product can be mixed with any liquid beverage.”

This product will boost sales because “patients are always looking for something that will improve their personal situation, so they most likely will try it,” Linden said.

Other products that remain “rocks in the category” at Bi-Lo are Pepcid AC, Zantac, Pepto-Bismol and Tums, according to Smith.

Pepcid AC from Johnson & Johnson/ Merck Consumer Pharmaceuticals Co., New Brunswick, N.J., was the third-highest-selling brand of antacid tablets, according to IRI, following private-label products, which ranked second.

Pepcid AC sales were at $68.7 million; however, dollar sales were down 8.25%, while sales for private-label antacid tablets were up 4.89% to $126 million.

Zantac 150 antacid tablets from Pfizer, New York, ranked fourth, up 21.12% to $66.6 million. Pepcid Complete Antacid Tablets — at $54.1 million, up 14.3% — were fifth, while Gas-X antacid tablets from Novartis Consumer Health, Parsippany, N.J., came in sixth, up 18% at $46.4 million.

Pepto-Bismol, from Proc-ter & Gamble, was first in the stomach remedy liquid/powder category, up 4.31% to $61.1 million, IRI reported.

“Prilosec, Pepcid and Zantac 150 continue to perform well at Publix,” noted Maria Brous, spokeswoman for Publix Super Markets, Lakeland, Fla.

The majority of these popular products target heartburn, also known as gastroesophageal reflux disease, or GERD. “It would be fair to say that America, for many health conditions, is undermedicated,” said consultant Jim Wisner, president, Wisner Marketing Group, Libertyville, Ill. “GERD would be among the more prevalent of those, with the risk of esophageal damage — and if you're not treating acid reflux, it's greater.”